China Shineway Pharmaceutical Group Limited - Asset Resilience Ratio

Latest as of December 2025: 3.49%

China Shineway Pharmaceutical Group Limited (C1S) has an Asset Resilience Ratio of 3.49% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of China Shineway Pharmaceutical Group Limi to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€376.64 Million

≈ $440.33 Million USD Cash + Short-term Investments

Total Assets

€10.78 Billion

≈ $12.60 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how China Shineway Pharmaceutical Group Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see C1S total asset value.

Liquid Assets Composition Over Time

This chart breaks down China Shineway Pharmaceutical Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read China Shineway Pharmaceutical Group Limi (C1S) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€376.64 Million	3.49%
Total Liquid Assets	€376.64 Million	3.49%

Asset Resilience Insights

Limited Liquidity: China Shineway Pharmaceutical Group Limited maintains only 3.49% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

China Shineway Pharmaceutical Group Limited Industry Peers by Asset Resilience Ratio

Compare China Shineway Pharmaceutical Group Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for China Shineway Pharmaceutical Group Limited (2017–2025)

The table below shows the annual Asset Resilience Ratio data for China Shineway Pharmaceutical Group Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	3.49%	€376.64 Million ≈ $440.33 Million	€10.78 Billion ≈ $12.60 Billion	+0.01pp
2024-12-31	3.49%	€350.02 Million ≈ $409.21 Million	€10.04 Billion ≈ $11.74 Billion	+3.28pp
2023-12-31	0.21%	€20.00 Million ≈ $23.38 Million	€9.57 Billion ≈ $11.19 Billion	-0.04pp
2022-12-31	0.25%	€20.23 Million ≈ $23.65 Million	€8.23 Billion ≈ $9.62 Billion	+0.14pp
2018-12-31	0.11%	€7.19 Million ≈ $8.41 Million	€6.73 Billion ≈ $7.87 Billion	-0.15pp
2017-12-31	0.25%	€16.91 Million ≈ $19.77 Million	€6.67 Billion ≈ $7.79 Billion	--

pp = percentage points

About China Shineway Pharmaceutical Group Limited

F:C1S Germany Drug Manufacturers - Specialty & Generic

Market Cap

$781.58 Million

€668.53 Million EUR

Market Cap Rank

#10389 Global

#1225 in Germany

Share Price

€0.89

Change (1 day)

-2.21%

52-Week Range

€0.80 - €1.09

All Time High

€1.25